LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT. (2019). Voprosy Onkologii, 65(3), 386-392. https://doi.org/10.37469/0507-3758-2019-65-3-386-392